Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NGFR | P08138 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889826 | 0.95 | KMT2A (0.40) | KDM4EALDH1A1HSD17B10LMNANGFR | |
| SCHEMBL889850 | 0.88 | SIRT1 (0.41) | KDM4EALDH1A1HSD17B10LMNAGAA | |
| SCHEMBL14156402 | 0.87 | HSD17B10 (0.43) | KDM4EALDH1A1HSD17B10LMNANGFR | |
| SCHEMBL21778550 | 0.84 | RAB9A (0.41) | GAAKMT2AMEN1POLBSIRT1 | |
| SCHEMBL20764331 | 0.83 | NOTUM (0.44) | KDM4EALDH1A1HSD17B10LMNAKMT2A | |
| SCHEMBL13183210 | 0.82 | RAB9A (0.41) | KDM4EALDH1A1HSD17B10LMNANGFR | |
| SCHEMBL13183213 | 0.81 | POLB (0.40) | KDM4EALDH1A1LMNAGAAKMT2A | |
| SCHEMBL18165247 | 0.81 | PLG (0.40) | KDM4EALDH1A1HSD17B10LMNAGAA | |
| SCHEMBL889973 | 0.81 | RAB9A (0.43) | HSD17B10GAAKMT2AMEN1POLB | |
| SCHEMBL13273870 | 0.81 | HSD17B10 (0.44) | KDM4EALDH1A1HSD17B10LMNANGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1068358-B1 | OLIGONUCLEOTIDES CONTAINING PYRAZOLO 3,4-D]PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2006-03-15 | — | — | EP | claimed |
| US-20030143602-A1 | Oligonucleotides containing pyrazolo[3,4-d]pyrimidines for hybridization and mismatch discrimination | DRUG ROYALTY LP1 (CA) | 2003-07-31 | — | — | US | claimed |
| US-6485906-B2 | DETECTING PREFERENTIAL NUCLEOTIDE SEQUENCES IN SAMPLE; OBTAIN NUCLEOTIDE SEQUENCES, INCUBATE WITH PRIMERS, DETECT SIGNAL DETERMINING THE DEGREE OF HYBRIDIZATION | EPOCH PHARMACEUTICALS, INC. | 2002-11-26 | — | — | US | claimed |
| US-20020146690-A1 | OLIGONUCLEOTIDES CONTAINING PYRAZOLO[3,4-D] PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION | ELITECHGROUP B.V. (NL) | 2002-10-10 | — | — | US | claimed |
| US-6127121-A | DISTINGUISHING POLYNUCLEOTIDES WITH RELATED SEQUENCES BY SEPARATELY INCUBATING EACH OF THE POLYNUCLEOTIDES WITH THE MODIFIED OLIGONUCLEOTIDE UNDER HYBRIDIZATION CONDITIONS AND DETERMINING THE DEGREES OF HYBRIDIZATION | EPOCH PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| CN-117940578-A | Hybridization probes containing fluorinated carbon chains and related methods | 因美纳有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-9932643-B2 | Detection of methicillin-resistant Staphylococcus aureus | ELITECHGROUP B.V. (NL) | 2018-04-03 | — | — | US | disclosed |
| US-20170183717-A1 | DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | ELITECHGROUP MDX LLC | 2017-06-29 | — | — | US | disclosed |
| US-9677142-B2 | Detection of methicillin-resistant Staphylococcus aureus | ELITECHGROUP B.V. (NL) | 2017-06-13 | — | — | US | disclosed |
| EP-2801626-B1 | Detection of methicillin-resistant staphylococcus aureus | ELITECHGROUP B V (NL) | 2016-04-06 | — | — | EP | disclosed |
| US-20150275274-A1 | DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | ELITECH HOLDING B.V. | 2015-10-01 | — | — | US | disclosed |
| EP-2714939-B1 | DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | ELITECH HOLDING BV (NL) | 2015-04-15 | — | — | EP | disclosed |
| EP-1224332-A1 | HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS | Epoch Biosciences, Inc. (US) | 2002-07-24 | — | — | EP | disclosed |
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | MICROPROBE | 2002-05-02 | — | — | US | disclosed |
| US-6312894-B1 | HYBRIDIZATION OF OLIGONUCLEOTIDES AND MINOR GROOVE BINDER COMBINATION; WHERE THE MINOR GROOVE BINDER BINDS IN A NON-INTERCALATING MANNER WITH A HIGHER ASSOCIATION CONSTANT | EPOCH PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001031063-A1 | HYBRIDIZATION-TRIGGERED FLUORESCENT DETECTION OF NUCLEIC ACIDS | EPOCH BIOSCIENCES, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| US-6127121-A | DISTINGUISHING POLYNUCLEOTIDES WITH RELATED SEQUENCES BY SEPARATELY INCUBATING EACH OF THE POLYNUCLEOTIDES WITH THE MODIFIED OLIGONUCLEOTIDE UNDER HYBRIDIZATION CONDITIONS AND DETERMINING THE DEGREES OF HYBRIDIZATION | EPOCH PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6084102-A | THE OLIGONUCLEOTIDE IS COMPLEMENTARY TO A TARGET SEQUENCE OF SINGLE STRANDED OR DOUBLE STRANDED DNA, RNA OR HYBRIDS AND, WHEN USED AS A PROBE, BINDS MORE STRONGLY BECAUSE OF THE BOUND MINOR GROVE BINDER; MEDICAL DIAGNOSIS; ANTISENSE THERAPY | EPOCH PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5801155-A | Covalently linked oligonucleotide minor grove binder conjugates | EPOCH PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| CN-1186496-A | Covalently bound oligonucleotide minor groove binder conjugates | IBORCH PHARMACEUTICAL CORP (US) | 1998-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052482-A1 | Covalently linked oligonucleotide minor grove binder conjugates | CD2BP2, MICA, SELPLG | KDM4E 3579/4885ALDH1A1 3137/4885HSD17B10 3310/4885 |
| US-20020146690-A1 | OLIGONUCLEOTIDES CONTAINING PYRAZOLO[3,4-D] PYRIMIDINES FOR HYBRIDIZATION AND MISMATCH DISCRIMINATION | DPYD, DTYMK, DDX41 | KDM4E 4262/4885ALDH1A1 3169/4885HSD17B10 4619/4885 |
| US-20030143602-A1 | Oligonucleotides containing pyrazolo[3,4-d]pyrimidines for hybridization and mismatch discrimination | DPYD, DTYMK, DDX41 | KDM4E 4262/4885ALDH1A1 3169/4885HSD17B10 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.